Press Releases

New Data Validates CyberKnife SBRT for Prostate Cancer Treatment SUNNYVALE, Calif., May 21, 2013 – Accuray Incorporated (Nasdaq: ARAY), announced today the publication of study results involving hundreds of prostate cancer patients treated with the CyberKnife® Robotic Radiosurgery System, the most widely used form of prostate stereotactic body radiation therapy (SBRT). The study followed 304 patients for a median of 5 years, and many to 6 years post-treatment and found that 97 percent of patients with low-risk and 90.7% of patients with intermediate-risk prostate cancer remained cancer-free throughout that time. The CyberKnife treatment was also shown to be minimally harmful, producing low levels of toxicity that are similar to the level produced by other radiation treatment options including brachytherapy. Preservation of sexual function was achieved for 75 percent of patients who were sexually potent prior to CyberKnife treatment. The positive quality of life outcomes, low side effects, and brief duration of CyberKnife treatment are especially encouraging for men weighing their many treatment options. Read More »

Accuray Provides Clarification on Recently Initiated Voluntary Recalls SUNNYVALE, Calif., April 18, 2013 – Accuray Incorporated (Nasdaq: ARAY) announced today clarification on two voluntary recalls that the company initiated on March 19, 2013. In keeping with its commitment to patient safety and total quality management, Accuray has voluntarily implemented a recall of two separate components from its CyberKnife® product line: the Iris™ Variable Aperture Collimator and the RoboCouch® Patient Positioning System. The affected parts are manufactured by third-party suppliers and are being removed from the system because they failed to meet the company’s specifications and standards for quality. Read More »

First Patient Treated Worldwide with the new TomoEDGE™ Dynamic Jaws Technology SUNNYVALE, Calif., April 4, 2013 – Accuray Incorporated (Nasdaq: ARAY), announced today that Heidelberg University Hospital, Germany, has treated the world’s first patients with the new TomoEDGE™ Dynamic Jaws technology combined with VoLO™ Planning as part of its TomoTherapy® System. The new TomoEDGE Dynamic jaws technology was introduced at ASTRO 2012 as the newest evolution to the TomoTherapy System. The managing director of the department of radiotherapy, Jürgen Debus, M.D., and Florian Sterzing, M.D., radiation oncologist, both with Heidelberg University Hospital, were in charge of these first treatments at Heidelberg University Hospital. Read More »